Chenguang Biotech Group Working Capital to Net Assets Ratio
Chenguang Biotech Group working capital to net assets ratio. Chenguang Biotech Group (300138) has a Working Capital to Net Assets ratio of 47.9% as of June 2026. Working capital of CN¥1.66 Billion (current assets of CN¥7.54 Billion minus current liabilities of CN¥5.89 Billion) is measured against net assets of CN¥3.46 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Chenguang Biotech Group's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Chenguang Biotech Group (2007–2025)
Working capital to net assets ratio of Chenguang Biotech Group from 2007 to 2025. This chart shows how Chenguang Biotech Group's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of June 2026, the ratio stands at 47.9%, reflecting working capital of CN¥1.66 Billion against net assets of CN¥3.46 Billion CNY. See how many days can Chenguang Biotech Group fund operations to measure how many days the company can operate on defensive assets alone.
Chenguang Biotech Group Working Capital to Net Assets Ratio by Year (2007–2025)
Chenguang Biotech Group working capital to net assets ratio by year from 2007 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Chenguang Biotech Group from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Chenguang Biotech Group assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 47.9% | CN¥1.65 Billion | CN¥3.44 Billion | CN¥7.43 Billion | CN¥5.78 Billion | ▼ -22.2 pp |
| 2024 | 70.1% | CN¥2.21 Billion | CN¥3.15 Billion | CN¥6.81 Billion | CN¥4.60 Billion | ▲ +1.8 pp |
| 2023 | 68.4% | CN¥2.41 Billion | CN¥3.53 Billion | CN¥6.37 Billion | CN¥3.95 Billion | ▲ +0.9 pp |
| 2022 | 67.5% | CN¥2.17 Billion | CN¥3.21 Billion | CN¥4.93 Billion | CN¥2.76 Billion | ▲ +21.0 pp |
| 2021 | 46.5% | CN¥1.29 Billion | CN¥2.78 Billion | CN¥3.98 Billion | CN¥2.68 Billion | ▼ -25.6 pp |
| 2020 | 72.2% | CN¥1.49 Billion | CN¥2.06 Billion | CN¥2.91 Billion | CN¥1.43 Billion | ▲ +28.6 pp |
| 2019 | 43.6% | CN¥759.09 Million | CN¥1.74 Billion | CN¥3.19 Billion | CN¥2.43 Billion | ▼ -1.4 pp |
| 2018 | 45.0% | CN¥782.90 Million | CN¥1.74 Billion | CN¥2.34 Billion | CN¥1.56 Billion | ▼ -6.0 pp |
| 2017 | 51.0% | CN¥828.26 Million | CN¥1.62 Billion | CN¥2.02 Billion | CN¥1.20 Billion | ▼ -5.0 pp |
| 2016 | 56.0% | CN¥853.31 Million | CN¥1.52 Billion | CN¥1.77 Billion | CN¥912.30 Million | ▼ -3.0 pp |
| 2015 | 58.9% | CN¥840.83 Million | CN¥1.43 Billion | CN¥1.35 Billion | CN¥506.92 Million | ▲ +13.4 pp |
| 2014 | 45.6% | CN¥459.54 Million | CN¥1.01 Billion | CN¥904.53 Million | CN¥444.99 Million | ▲ +2.6 pp |
| 2013 | 43.0% | CN¥425.86 Million | CN¥990.39 Million | CN¥1.01 Billion | CN¥583.33 Million | ▼ -3.5 pp |
| 2012 | 46.5% | CN¥463.90 Million | CN¥997.86 Million | CN¥889.14 Million | CN¥425.24 Million | ▼ -12.9 pp |
| 2011 | 59.4% | CN¥575.48 Million | CN¥968.71 Million | CN¥711.78 Million | CN¥136.29 Million | ▼ -16.8 pp |
| 2010 | 76.2% | CN¥711.41 Million | CN¥933.05 Million | CN¥922.16 Million | CN¥210.75 Million | ▲ +43.5 pp |
| 2009 | 32.8% | CN¥69.09 Million | CN¥210.67 Million | CN¥253.46 Million | CN¥184.37 Million | ▼ -8.3 pp |
| 2008 | 41.1% | CN¥60.79 Million | CN¥147.93 Million | CN¥293.00 Million | CN¥232.21 Million | ▼ -8.1 pp |
| 2007 | 49.2% | CN¥50.07 Million | CN¥101.70 Million | CN¥131.07 Million | CN¥81.00 Million | — |